Jane Street
RDHL

Jane Street’s Redhill Biopharma RDHL Stock Holding History

Jane Street’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11
Closed -$27K – 10650
2022
Q1 		$27K Sell
11
-11
-50% -$26.1K ﹤0.01% 9861
2021
Q4 		$57K Sell
22
-55
-71% -$220K ﹤0.01% 9487
2021
Q3 		$354K Buy
+77
New +$522K ﹤0.01% 7874

Other funds holding RDHL

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
CPA
Capital Performance Advisors Walnut Creek, California $1.5B AUM 21.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jane Street's RDHL Position: Q3 2024 in Review

Jane Street sold out of Redhill Biopharma (RDHL) in Q3 2024, closing a stake of 1,886 shares — an estimated $17.3K sold.

Jane Street first reported a position in RDHL in Q1 2017 and held it in 11 quarters. The position peaked at $384K in Q2 2019. 11 funds tracked by Wall St. Rank hold RDHL as of Q3 2024.

  • Jane Street reported no remaining Redhill Biopharma position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 1,886 Redhill Biopharma shares in Q3 2024, an estimated $17.3K.
  • Jane Street first reported a position in Redhill Biopharma in Q1 2017 and held it in 11 quarters.
  • Jane Street's Redhill Biopharma position peaked at $384K in Q2 2019.
  • 11 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.